

“Technology that allows the development of highly sensitive & specific blood tests to early detect several types of cancer.”

THE PROBLEM



Liver cancer constitutes the second leading cause of cancer-related death in the world. **Liver cancer** is **asymptomatic in early stages** and diagnosis generally occurs when the disease has progressed to an advanced stage with a low probability of being effectively treated. With an early diagnosis cure is possible in 50% of cases, and in the rest, effective control is achievable. Thus, there is the **need to develop** a standalone, high-throughput, and cost-effective **early diagnostic tool**.



700.000 new cases of **liver cancer** globally (2018)



782.000 deaths / year 2018



HCC accounts for **75-80%** cases of liver cancer (US)



50% cases cure possible through early diagnostic



50M€ Market Size (EU)

THE SOLUTION



Yliver is a blood test that detects alpha-fetoprotein autoantibodies, which appears up to 4 years before the first symptoms.

A high throughput and reliable *in vitro* platform for serum autoantibody-like biomarker identification and quantification.

- The technology increases the immunogenicity of antigens in ELISA test for protein detection and quantification.

KEY BENEFITS



Sensitivity increase from 46% to **100%**



Limits the use of imaging tests



Cost-effective diagnostic tool



Versatile technology applicable to other cancer types and autoimmune diseases.

MILESTONES

2017 **Proof of Concept**

2019 **Startup Creation**

2019 **Patent application**

2020 **Kick Off**

2021 **Clinical feasibility**

2025 **Exit**

AWARDS

5.000€
(2018)



30.000€
(2019)



FUNDING GOALS

For **peptide ID, peptide protection** and **clinical validation**



- 17% Research
- 45% Human Resources
- 35% Outsourcing Services
- 3% Material

KEYMETRICS

10€ Price test

2€ Production cost

USD 8,25bn Global Liver Cancer diagnostic market (2017)

460M€ Global Cirrhosis Market

5M€ Beachhead market (cirrhosis, Spain)

€26M Savings in Spain / year

2X Survival rate

MANAGING TEAM



Xavier Gallego
Co-Founder & CEO



Juan F. Delgado
Co-Founder & CMO

